NVO

Business Context and Reporting Period

Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First half of 2024 (January 1, 2024 – June 30, 2024)
Business Overview: Novo Nordisk is a global healthcare company focused on diabetes, obesity, and rare diseases. The period was characterized by robust sales growth driven by GLP-1-based treatments for diabetes and obesity, offset by supply constraints and a significant R&D impairment loss.

Key Financial Metrics (H1 2024)

*CER: Constant Exchange Rates (average 2023 rates).

Material Changes vs. Prior Period

• Sales Growth: Total sales increased 24% (25% at CER). Growth was driven by Diabetes and Obesity care (+26% reported, +27% CER), specifically GLP-1 diabetes products (+32%) and Obesity care (+37%). Rare disease sales declined 4%.
• Geographic Performance: North America Operations sales grew 36% (36% CER), while International Operations grew 9% (11% CER). US sales were positively impacted by gross-to-net adjustments related to prior years.
• Cost Structure: R&D costs surged 79% (78% CER) to DKK 24.8 billion, primarily due to increased late-stage clinical trials and a DKK 5.7 billion impairment loss related to the ocedurenone asset. Sales and distribution costs rose 5%.
• Profitability: Operating profit grew 18%, but margins compressed slightly due to capacity expansion costs and the ocedurenone impairment. Net profit grew 16%.
• Cash Flow: Free cash flow decreased 9% to DKK 41.3 billion, reflecting higher capital expenditures for capacity expansion and intangible asset acquisitions.

Guidance, Outlook, and Risks

2024 Full-Year Outlook (Updated)

• Sales Growth: Expected 22-28% at CER (previously 19-27%). Reported growth expected to be ~1 percentage point lower than CER due to FX.
• Operating Profit Growth: Expected 20-28% at CER (previously 22-30%). Reported growth expected to be ~1 percentage point lower than CER.
• Capital Expenditure: Expected around DKK 45 billion.
• Free Cash Flow: Expected between DKK 59 and 69 billion.

Management Commentary & R&D Updates

• Supply Constraints: Continued high demand for Ozempic and Wegovy has led to periodic supply constraints and drug shortage notifications globally. Demand for Wegovy in the US exceeds supply.
• Positive Developments: Successful Phase 3 FRONTIER 2 trial for Mim8 (haemophilia); Positive CHMP opinion for Wegovy label update regarding cardiovascular risk reduction; Awiqli approved in EU, Japan, and China.
• Negative Developments: Phase 3 CLARION-CKD trial for ocedurenone stopped for futility (resulting in DKK 5.7B impairment); FDA issued a Complete Response Letter for insulin icodec in the US.

Risks and Contingencies

• Legal: Ongoing litigation regarding the 340B Drug Pricing Program in the US; outcomes could materially impact financial position.
• Operational: Supply chain disruptions and capacity limitations affecting product availability.
• Regulatory: Potential impacts from healthcare reforms and legislative changes.

Key Facts for Investor Verification

• Impairment Impact: Verify the DKK 5.7 billion impairment charge related to ocedurenone and its specific impact on R&D expenses and operating profit.
• Supply Chain Capacity: Assess the timeline for resolving supply constraints for GLP-1 products (Ozempic, Wegovy) and the impact of the DKK 45 billion capital expenditure plan on future capacity.
• US Gross-to-Net Adjustments: Confirm the sustainability of US sales growth, which was partially driven by gross-to-net adjustments related to prior years.
• Regulatory Status: Monitor the status of the insulin icodec application following the FDA Complete Response Letter and the resubmission of concizumab.
• 340B Litigation: Track the status of pending appeals in the US Court of Appeals regarding the 340B Drug Pricing Program.